(Q39783619)

14 September 2017

Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling (English)

1 reference

14 September 2017

A Yalcin

1

1 reference

14 September 2017

B Clem

2

1 reference

14 September 2017

S Makoni

3

1 reference

14 September 2017

A Clem

4

1 reference

14 September 2017

K Nelson

5

1 reference

14 September 2017

J Thornburg

6

1 reference

14 September 2017

D Siow

7

1 reference

14 September 2017

A N Lane

8

1 reference

14 September 2017

S E Brock

9

1 reference

14 September 2017

U Goswami

10

1 reference

14 September 2017

J W Eaton

11

1 reference

14 September 2017

S Telang

12

1 reference

14 September 2017

J Chesney

13

1 reference

14 September 2017

language of work or name

English

0 references

publication date

26 October 2009

1 reference

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

1

1 reference

14 September 2017

139-149

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.317

14 September 2017

0 references

cites work

Choline phospholipid metabolism: a target in cancer cells?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Structure and function of choline kinase isoforms in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline kinase alpha depletion selectively kills tumoral cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Requirement of phospholipase D1 activity in H-RasV12-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline kinase alpha in cancer prognosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline metabolism in cancer: implications for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline kinase inhibitors as a novel approach for antiproliferative drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Tumour-released exosomes and their implications in cancer immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Alterations of choline phospholipid metabolism in ovarian tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Ras isoform abundance and signalling in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

The role of targeting mammalian target of rapamycin in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Pharmacological importance of phospholipase D and phosphatidic acid in the regulation of the mitogen-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

The oncoprotein H-RasV12 increases mitochondrial metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Ras transformation requires metabolic control by 6-phosphofructo-2-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Targeting aspartate aminotransferase in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Control of EGF receptor signaling by clathrin-mediated endocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

21 January 2018

PA promoted to manager

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Breast tumors: evaluation with P-31 MR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Cotargeting survival signaling pathways in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

Epithelial cell motility is triggered by activation of the EGF receptor through phosphatidic acid signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.317

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.317

1 reference

Dimensions Publication ID

14 September 2017

0 references

1 reference